Cargando…

Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study

BACKGROUND: Severity/mortality risk scores and disease characteristics may assist in deciding whether patients with community-acquired bacterial pneumonia (CABP) require outpatient treatment or hospitalization. The phase 3 OPTIC (Omadacycline for Pneumonia Treatment In the Community) study enrolled...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramirez, Julio, Deck, Daniel H, Eckburg, Paul B, Curran, Marla, Das, Anita F, Kirsch, Courtney, Manley, Amy, Tzanis, Evan, McGovern, Paul C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Major Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8212944/ https://www.ncbi.nlm.nih.gov/pubmed/34160474 http://dx.doi.org/10.1093/ofid/ofab135

Ejemplares similares

110. Clinical Outcomes of Patients with Secondary Bacteremia in the Omadacycline Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2019)

Clinical Efficacy of Patients With Secondary Bacteremia Treated With Omadacycline: Results From Phase 3 Acute Bacterial Skin and Skin Structure Infections and Community-Acquired Bacterial Pneumonia Studies
por: Sakoulas, George, et al.
Publicado: (2021)

Omadacycline for Acute Bacterial Skin and Skin Structure Infections
por: Abrahamian, Fredrick M, et al.
Publicado: (2019)

Early Clinical Response in Community-acquired Bacterial Pneumonia: From Clinical Endpoint to Clinical Practice
por: Ramirez, Julio A, et al.
Publicado: (2019)

1347. Omadacycline for Acute Bacterial Skin and Skin Structure Infections: Integrated Analysis of Randomized Clinical Trials
por: Abrahamian, Fredrick M, et al.
Publicado: (2018)

1356. Improvement in Quality of Life for Adults With Acute Bacterial Skin and Skin Structure Infections Following Treatment With Omadacycline or Linezolid
por: Tzanis, Evan, et al.
Publicado: (2018)

1561. Omadacycline Pharmacokinetics: Influence of Mortality Risk Score Among Patients with Community-Acquired Bacterial Pneumonia
por: Lakota, Elizabeth A, et al.
Publicado: (2019)

1687. Omadacycline in Female Adults With Acute Pyelonephritis: Results from a Randomized, Double-Blind, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

The Effect of Verapamil, a P-gp Inhibitor, on the Pharmacokinetics, Safety, and Tolerability of Omadacycline in Healthy Adults: A Phase I, Open-Label, Single-Sequence Study
por: Hunt, Thomas L., et al.
Publicado: (2020)

Omadacycline Pharmacokinetics: Influence of Mortality Risk Score among Patients with Community-Acquired Bacterial Pneumonia
por: Trang, M., et al.
Publicado: (2022)

An Integrated Safety Summary of Omadacycline, a Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2019)

1374. Integrated Safety Summary of Omadacycline: A Novel Aminomethylcycline Antibiotic
por: Opal, Steven, et al.
Publicado: (2018)

734. Modeling the Pharmacokinetics and Pharmacodynamics of Intravenous and Oral Omadacycline with and without a Loading Dose
por: Friedrich, Lawrence, et al.
Publicado: (2019)

700. Safety and Efficacy of Omadacycline in Patients with Diabetes in Phase 3 Clinical Studies
por: Pai, Manjunath P, et al.
Publicado: (2019)

1688. Omadacycline in Female Adults With Cystitis: Results From a Randomized, Double-Blinded, Adaptive Phase 2 Study
por: Overcash, J Scott, et al.
Publicado: (2020)

Effect of Food on the Bioavailability of Omadacycline in Healthy Participants
por: Tzanis, Evan, et al.
Publicado: (2016)

Decision Analysis: Omadacycline Relative to Moxifloxacin Among Hospitalized Community-Acquired Bacterial Pneumonia Patients at Risk of Clostridioides difficile Infection
por: Lodise, Thomas P., et al.
Publicado: (2021)

Evaluation of the Impact of Comorbidities on Omadacycline Pharmacokinetics
por: Trang, M., et al.
Publicado: (2023)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function
por: Berg, Jolene K., et al.
Publicado: (2018)

Omadacycline for the Treatment of Mycobacterium abscessus Disease: A Case Series
por: Pearson, Jeffrey C, et al.
Publicado: (2020)

Long-term Safety and Tolerability of Omadacycline for the Treatment of Mycobacterium abscessus Infections
por: Mingora, Christina M, et al.
Publicado: (2023)

Safety and Pharmacokinetics of the Aminomethylcycline Antibiotic Omadacycline Administered to Healthy Subjects in Oral Multiple-Dose Regimens
por: Bundrant, Lu Ann, et al.
Publicado: (2018)

733. Pharmacokinetic–Pharmacodynamic (PK–PD) Analyses for Alanine Aminotransferase (ALT) Using Phase 3 Data From Omadacycline (OMC)-Treated Patients
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

Lefamulin vs moxifloxacin for community-acquired bacterial pneumonia
por: Tang, Hung-Jen, et al.
Publicado: (2020)

Community-Acquired Pneumonia in the Immunocompromised Host: Epidemiology and Outcomes
por: Ramirez, Julio A, et al.
Publicado: (2023)

Efficacy and Safety of Omadacycline Versus Linezolid in Acute Bacterial Skin and Skin Structure Infections in Persons Who Inject Drugs
por: Moran, Gregory J., et al.
Publicado: (2022)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

Pharmacokinetics, Safety, and Clinical Outcomes of Omadacycline in Women with Cystitis: Results from a Phase 1b Study
por: Overcash, J. Scott, et al.
Publicado: (2019)

Efficacy of Omadacycline or Vancomycin Combined With Germinants for Preventing Clostridioides difficile Relapse in a Murine Model
por: Budi, Noah D, et al.
Publicado: (2022)

Procalcitonin as a Marker of Etiology in Adults Hospitalized With Community-Acquired Pneumonia
por: Self, Wesley H., et al.
Publicado: (2017)

Comparison of Omadacycline and Tigecycline Pharmacokinetics in the Plasma, Epithelial Lining Fluid, and Alveolar Cells of Healthy Adult Subjects
por: Gotfried, Mark H., et al.
Publicado: (2017)

Model-Based Efficacy and Toxicity Comparisons of Moxifloxacin for Multidrug-Resistant Tuberculosis
por: Yun, Hwi-Yeol, et al.
Publicado: (2021)

Increased Moxifloxacin Dosing Among Patients With Multidrug-Resistant Tuberculosis With Low-Level Resistance to Moxifloxacin Did Not Improve Treatment Outcomes in a Tertiary Care Center in Mumbai, India
por: Tornheim, Jeffrey A, et al.
Publicado: (2021)

Health-Related Quality of Life as Measured by the 12-Item Short-Form Survey Among Adults With Community-Acquired Bacterial Pneumonia who Received Either Lefamulin or Moxifloxacin in 2 Phase III Randomized, Double-Blind, Double-Dummy Clinical Trials
por: Lodise, Thomas P, et al.
Publicado: (2020)

Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections
por: Pai, Manjunath P, et al.
Publicado: (2021)

Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States
por: Diaz, Maureen H., et al.
Publicado: (2015)

Epidemiology and Outcomes of Community-Acquired Escherichia coli Pneumonia
por: John, Teny M, et al.
Publicado: (2021)

Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019)

gyrA Mutations in Mycoplasma genitalium and Their Contribution to Moxifloxacin Failure: Time for the Next Generation of Resistance-Guided Therapy
por: Murray, Gerald L, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p28qncvpc0qjqon876renqftot